NasdaqCM - Delayed Quote • USD
Landos Biopharma, Inc. (LABP)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 7:44 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -1 | -0.87 | -2.19 | -1.68 |
| Low Estimate | -1.12 | -1.12 | -2.35 | -2.07 |
| High Estimate | -0.88 | -0.63 | -2.03 | -1.3 |
| Year Ago EPS | -0.9 | -0.63 | -3.5 | -2.19 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.95 | -1.1 | -0.88 | -0.91 |
| EPS Actual | -0.9 | -0.63 | -0.94 | -0.99 |
| Difference | 0.05 | 0.47 | -0.06 | -0.08 |
| Surprise % | 5.30% | 42.70% | -6.80% | -8.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1 | -0.87 | -2.19 | -1.68 |
| 7 Days Ago | -1 | -0.87 | -2.19 | -1.68 |
| 30 Days Ago | -0.88 | -0.91 | -2.5 | -1.13 |
| 60 Days Ago | -0.88 | -0.91 | -2.5 | -1.13 |
| 90 Days Ago | -0.65 | -0.71 | -2.61 | -1.75 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | LABP | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -11.10% | -- | -- | 1.60% |
| Next Qtr. | -38.10% | -- | -- | 10.50% |
| Current Year | 37.40% | -- | -- | 5.20% |
| Next Year | 23.30% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Downgrade | HC Wainwright & Co.: Buy to Neutral | 4/1/2024 |
Related Tickers
ANEB Anebulo Pharmaceuticals, Inc.
2.7800
+1.09%
DSGN Design Therapeutics, Inc.
3.7000
-1.07%
INBX Inhibrx, Inc.
34.32
-0.38%
LENZ LENZ Therapeutics, Inc.
16.02
-8.40%
IPHA Innate Pharma S.A.
2.4400
+1.67%
KROS Keros Therapeutics, Inc.
58.28
-1.14%
EIGRQ Eiger BioPharmaceuticals, Inc.
2.3900
+9.13%
BCYC Bicycle Therapeutics plc
23.45
-4.25%
AKTX Akari Therapeutics, Plc
1.1662
-0.32%
IVA Inventiva S.A.
3.3300
+0.60%